Real-life experiences with galcanezumab and predictors for treatment response in Turkey [PDF]
BMC Neurology, 2023 Background The complexity of clinical practice extends far beyond the controlled settings of trials, and there is a need for real-world studies aimed at identifying which patients will respond to anti-CGRP monoclonal antibodies in different countries ...
Pınar Yalinay Dikmen +16 more
doaj +2 more sources
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study [PDF]
Current Medical Research and Opinion, 2022 Galcanezumab; Chronic migraine; Preventive treatmentGalcanezumab; Migraña crónica; Tratamiento preventivoGalcanezumab; Migranya crònica; Tractament preventiuBackground Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was found to ...
Patricia Pozo-Rosich +2 more
exaly +3 more sources
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population [PDF]
Brain and Behavior, 2023 Background Galcanezumab is a monoclonal antibody acting against the calcitonin gene‐related peptide approved for the preventive treatment of migraine. The aim of this article is to explore its effectiveness and safety of galcanezumab in chronic migraine (
Simona Guerzoni +4 more
doaj +2 more sources
Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group [PDF]
Frontiers in NeurologyObjectiveThis prospective real-world study, conducted by the Greek Research Alliance for the Study of Headache and Pain (GRASP), aimed to evaluate the efficacy, tolerability and safety of subcutaneous galcanezumab 240 mg in reducing the frequency and ...
Michail Vikelis +8 more
doaj +2 more sources
Therapeutic Advances in Neurological Disorders, 2020 Background: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares
Dimos-Dimitrios D Mitsikostas
exaly +2 more sources
Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat [PDF]
The Journal of Headache and PainBackground Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine.
Nadine Friedrich +8 more
doaj +2 more sources
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) [PDF]
The Journal of Headache and Pain, 2019 Background Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM).
Stephen D. Silberstein +4 more
doaj +3 more sources
Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study [PDF]
The Journal of Headache and Pain, 2021 Background Chronic migraine (CM) and episodic migraine (EM) are associated with substantial headache-related disability, poor quality of life and global societal burden. In this subgroup analysis from the CONQUER study, we report efficacy outcomes from a
Rose Okonkwo +5 more
doaj +2 more sources
Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review. [PDF]
Front NeurolTargeting therapies; Migraine; Monoclonal antibodiesTeràpies dirigides; Migranya; Anticossos monoclonalsTerapias dirigidas; Migraña; Anticuerpos monoclonalesIntroduction: In the context of migraine preventive therapy, new therapeutic modalities such as ...
Pozo-Rosich P +5 more
europepmc +4 more sources
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab [PDF]
The Journal of Headache and PainBackground Chronic migraine (CM) is a highly disabling form of migraine in which patients have ≥ 15 headache days per month, of which at least 8 have the features of migraine. Galcanezumab is a monoclonal antibody to calcitonin gene-related peptide which
Hans-Christoph Diener +5 more
doaj +2 more sources